OncoMatch

OncoMatch/Clinical Trials/NCT04678648

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

Is NCT04678648 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including RSC-1255 Dose Escalation and RSC-1255 Dose Expansion for advanced malignant solid neoplasm.

Phase 1RecruitingRasCal Therapeutics, Inc.NCT04678648Data as of May 2026

Treatment: RSC-1255 Dose Escalation · RSC-1255 Dose ExpansionRSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

Check if I qualify

Extracted eligibility criteria

Cancer type

Tumor Agnostic

Non-Small Cell Lung Carcinoma

Colorectal Cancer

Glioblastoma

Pancreatic Cancer

Biomarker criteria

Required: KRAS any mutation

documented RAS mutations

Required: NRAS any mutation

documented RAS mutations

Required: HRAS any mutation

documented RAS mutations

Disease stage

Required: Stage IV

advanced or metastatic malignancy

Prior therapy

Must have received: any therapy known to provide clinical benefit

Participant is intolerant of existing therapy(ies) known to provide clinical benefit for their condition; Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit; Malignancy has progressed on standard therapy

Cannot have received: cancer therapy

Participants receiving cancer therapy at the time of enrollment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • University of California, Los Angeles (UCLA) Department of Medicine - Hematology/Oncology · Los Angeles, California
  • Sarah Cannon, SCRI Oncology Partners - Health One · Denver, Colorado
  • Sarah Cannon, SCRI Oncology Partners · Nashville, Tennessee

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify